title: Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer.
abstract: OBJECTIVE
  To investigate the correlation between expression of calreticulin and infiltration of lymphocytes in stage IIIB colon cancer.
  
  
  METHODS
  Sixty-eight pathologically-confirmed specimens were obtained from stage IIIB (T3N1M0) colon cancer patients who underwent radical resection between January 1999 and May 2002 at the Cancer Center of Sun Yat-Sen University, Guangzhou, China. Immunohistochemical analysis was performed to show infiltration of lymphocytes and expression of calreticulin in colon cancer. Association between calreticulin expression, infiltration of lymphocytes, and 5-year survival rate of patients was assessed.
  
  
  RESULTS
  The expression level of calreticulin was lower in cancer nest than in its adjacent normal epithelium since 61.8% (42/68) of the samples were stained with calreticulin in colon cancer. The expression of calreticulin in colon cancer was associated with the infiltration of CD45RO+ cells rather than with that of CD3+ cells. In addition, the stronger expression of calreticulin and the higher infiltration of CD3+ and CD45RO+ cells in colon cancer were associated with the higher 5-year survival rate of patients.
  
  
  CONCLUSIONS
  Expression of calreticulin is associated with infiltration of T-cells, which implies that a low expression level of molecular marker may represent a new mechanism underlying immune escape in colon cancer.
authors.affiliation: State Key Laboratory of Oncology in South China, Biotherapy Center, Sun Yat-sen University, 651 Dongfeng R E, Guangzhou 510060, Guangdong Province, China.
authors.forename: Rui-Qing
authors.initials: RQ
authors.lastname: Peng
authors.forename: Ying-Bo
authors.initials: YB
authors.lastname: Chen
authors.forename: Ya
authors.initials: Y
authors.lastname: Ding
authors.forename: Rong
authors.initials: R
authors.lastname: Zhang
authors.forename: Xing
authors.initials: X
authors.lastname: Zhang
authors.forename: Xing-Juan
authors.initials: XJ
authors.lastname: Yu
authors.forename: Zhi-Wei
authors.initials: ZW
authors.lastname: Zhou
authors.forename: Yi-Xin
authors.initials: YX
authors.lastname: Zeng
authors.forename: Xiao-Shi
authors.initials: XS
authors.lastname: Zhang
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D017252:CD3 Complex / Q000032:analysis; D037282:Calreticulin / Q000032:analysis*; D016009:Chi-Square Distribution; D003110:Colonic Neoplasms / Q000737:chemistry* / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D017493:Leukocyte Common Antigens / Q000032:analysis; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D016896:Treatment Outcome; D019139:Tumor Escape
chemical_list: D014408:Biomarkers, Tumor; D017252:CD3 Complex; D037282:Calreticulin; D017493:Leukocyte Common Antigens